Insmed (NASDAQ:INSM) COO Sells $247,688.57 in Stock

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 1,429 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $173.33, for a total transaction of $247,688.57. Following the sale, the chief operating officer directly owned 110,462 shares in the company, valued at $19,146,378.46. The trade was a 1.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Roger Adsett also recently made the following trade(s):

• On Thursday, January 8th, Roger Adsett sold 2,059 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total transaction of $358,616.03.
• On Wednesday, January 7th, Roger Adsett sold 802 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $140,406.14.

Insmed Stock Up 3.3%

INSM stock opened at $175.97 on Friday. Insmed, Inc. has a one year low of $60.40 and a one year high of $212.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The firm’s fifty day moving average is $190.04 and its 200 day moving average is $152.18. The firm has a market cap of $37.53 billion, a PE ratio of -28.43 and a beta of 1.08.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The firm had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. During the same quarter last year, the company posted ($1.27) EPS. The company’s revenue was up 52.4% on a year-over-year basis. On average, research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Preliminary/full‑year revenue and updated FY‑2025 guidance well above Street expectations — management cited ~ $606.4M revenue guidance vs. consensus near $520.7M, a key driver of the rally. Read More.
• Positive Sentiment: BRINSUPRI launch strong: company reported ~ $144.6M in BRINSUPRI revenue for the first full quarter of launch and ~ $172.7M for full‑year 2025 — supports multi‑blockbuster revenue narrative. Read More.
• Positive Sentiment: ARIKAYCE outperformance and 2026 guidance: ARIKAYCE generated ~ $433.8M in 2025, exceeding prior guidance; management expects $450M–$470M in 2026, underpinning recurring cash flow expectations. Read More.
• Neutral Sentiment: Clinical timeline updates: ENCORE (ARIKAYCE Phase 3) topline is now expected in March/April 2026 and CEDAR (brensocatib Phase 2b) topline in Q2 2026 — material catalysts but timing shifts may concentrate near‑term volatility. Read More.
• Neutral Sentiment: R&D cadence: new Phase‑3 PALM‑ILD start and plans for additional Phase‑3 programs (PAH, PPF, IPF) expand long‑term optionality but raise near‑term spend and execution risk. Read More.
• Neutral Sentiment: Media/retail interest: Jim Cramer highlighted INSM as “worth keeping an eye on,” which can boost retail liquidity but is not a fundamental endorsement. Read More.
• Negative Sentiment: Concentrated insider selling: multiple executives (CEO, CFO, COO and others) sold shares across Jan. 6–8 (reports aggregate ≈ $15M+ in sales), which can signal profit‑taking or create negative sentiment among some investors. Read More.
• Negative Sentiment: Investor litigation alert: Pomerantz LLP has opened an investor investigation into Insmed, introducing legal and reputational uncertainty until matters are resolved. Read More.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Wolfe Research set a $167.00 price objective on Insmed and gave the company an “outperform” rating in a research report on Thursday, December 18th. Morgan Stanley set a $157.00 price target on shares of Insmed in a report on Thursday. Rothschild & Co Redburn began coverage on shares of Insmed in a report on Thursday, December 4th. They set a “buy” rating and a $263.00 price objective on the stock. Redburn Partners set a $263.00 target price on shares of Insmed in a research report on Thursday, December 4th. Finally, TD Cowen reduced their price target on shares of Insmed from $269.00 to $241.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $205.64.

Institutional Investors Weigh In On Insmed

A number of large investors have recently modified their holdings of INSM. Chung Wu Investment Group LLC acquired a new position in Insmed during the second quarter worth about $173,000. Resolute Capital Asset Partners LLC acquired a new stake in Insmed in the 2nd quarter valued at about $2,748,000. Caxton Associates LLP purchased a new position in Insmed in the 1st quarter worth approximately $441,000. Assenagon Asset Management S.A. boosted its holdings in shares of Insmed by 84.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock worth $7,387,000 after purchasing an additional 33,626 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Insmed during the 2nd quarter worth approximately $5,578,000.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.